Document Detail


Rationale and design of the Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea--RICCADSA trial.
MedLine Citation:
PMID:  18663661     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Obstructive sleep apnoea (OSA) is common in coronary artery disease (CAD) and a possible cause of increased mortality. To date, there is a lack of randomized controlled trials to draw the conclusion that all CAD patients should be investigated for OSA and subsequently be treated with continuous positive airway pressure (CPAP). OBJECTIVE: The Randomized Intervention with CPAP in CAD and OSA (RICCADSA) trial is designed to address if CPAP treatment reduces the combined rate of new revascularization, myocardial infarction, stroke and cardiovascular mortality over a 3-year period in CAD patients with OSA. Secondary outcomes include cardiovascular biomarkers, cardiac function and maximal exercise capacity at 3-month- and 1-year follow-ups. PATIENTS AND METHODS: A sample of 400 CAD patients (100 non-sleepy OSA patients randomized to CPAP, 100 to non-CPAP; 100 sleepy OSA patients on CPAP, and 100 CAD patients without OSA) will be included. So far, 240 patients have been enrolled in the trial since December 31, 2005. CONCLUSION: The RICCADSA trial will contribute to defining the impact of CPAP on prognosis of CAD patients with OSA.
Authors:
Yüksel Peker; Helena Glantz; Eric Thunström; Anders Kallryd; Johan Herlitz; Jan Ejdebäck
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Scandinavian cardiovascular journal : SCJ     Volume:  43     ISSN:  1651-2006     ISO Abbreviation:  Scand. Cardiovasc. J.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-13     Completed Date:  2009-03-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9708377     Medline TA:  Scand Cardiovasc J     Country:  England    
Other Details:
Languages:  eng     Pagination:  24-31     Citation Subset:  IM    
Affiliation:
Sleep Medicine Unit, Department of Neurology and Rehabilitation Medicine, Skaraborg Hospital, Skövde, Sweden. yuksel.peker@lungall.gu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / metabolism
Cardiovascular Diseases / etiology,  mortality,  prevention & control*
Continuous Positive Airway Pressure* / adverse effects,  mortality
Coronary Artery Disease / complications,  mortality,  therapy*
Exercise Tolerance
Heart Function Tests
Humans
Myocardial Revascularization* / adverse effects,  mortality
Research Design
Sleep Apnea, Obstructive / complications,  mortality,  therapy*
Sweden / epidemiology
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation.
Next Document:  Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran s...